AMG 424
- Generic Name
- AMG 424
- Drug Type
- Biotech
- Background
AMG 424 is a novel, humanized, anti-CD3/CD38 bispecific monoclonal antibody being investigated for multiple myeloma.
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Xencor, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03445663
- Locations
- 🇦🇺
Research Site, Fitzroy, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath